Schering-Plough Reports Financial Results for 2007 Fourth Quarter,...(lion respectively. Schering-Plough ne...)

Schering-Plough net sales growth for the three and twelve months ended December 31, 2007 reflects a favorable foreign exchange impact of 7% and 4%, respectively.

NOTE: Adjusted net sales, defined as net sales plus an assumed 50 percent

of global cholesterol joint venture net sales, is a non-U.S. GAAP

measure used by management in evaluating the performance of the

Schering-Plough's overall business. Schering-Plough believes that

this performance measure contributes to a more complete

understanding by investors of the overall results of the company.

Schering-Plough provides this information to supplement the

reader's understanding of the importance to the company of its

share of results from the operations of the cholesterol joint

venture. Net sales (excluding the cholesterol joint venture net

sales) is required to be presented under U.S. GAAP. The

cholesterol joint venture's net sales are included as a component

of income from operations in the calculation of Schering-Plough's

"Equity income." Net sales of the cholesterol joint venture do not

include net sales of cholesterol products in non-joint venture

territories.